BP BioLabs
Member
Survodutide: How Does the GLP-1/Glucagon Dual Agonist Work?
Survodutide (BI 456906) is an investigational medication being studied for obesity and metabolic liver disease. What makes it different from traditional GLP-1 medications is that it targets two receptors: GLP-1 and glucagon.Why does the dual mechanism matter?
- GLP-1 receptor: involved in appetite regulation, food intake and glucose control.
- Glucagon receptor: involved in energy metabolism and liver function.
What do the clinical trials show?
The 2026 Phase 3 SYNCHRONIZE-1 trial, published in the New England Journal of Medicine, reported average weight reductions of 12.2% and 13.0% at 76 weeks in the two survodutide treatment groups, compared with 5.4% for placebo.
Researchers are also investigating its potential in metabolic dysfunction-associated steatotic liver disease (MASLD) and MASH.
One important point: gastrointestinal adverse events were common in the obesity trial, and long-term safety and efficacy still require continued evaluation.
Survodutide remains investigational and has not yet been approved for general use.
Sources:
- New England Journal of Medicine – SYNCHRONIZE-1 (2026)
- Nature Medicine – SYNCHRONIZE-MASLD (2026)
- Boehringer Ingelheim – Clinical development update
Shared for scientific and research discussion only.